{"result": "(\"entity\"<|>AMERICAN THYROID ASSOCIATION<|>ORGANIZATION<|>The American Thyroid Association is a professional organization that provides guidelines for the diagnosis and management of thyroid diseases, including medullary thyroid carcinoma.)\n##\n(\"entity\"<|>EUROPEAN THYROID ASSOCIATION<|>ORGANIZATION<|>The European Thyroid Association is a professional organization that offers guidelines for the diagnosis and treatment of thyroid-related conditions, including thyrotropin-secreting pituitary tumors.)\n##\n(\"entity\"<|>WELLS SA<|>PERSON<|>Wells SA is a prominent researcher involved in the study and management of medullary thyroid carcinoma and has contributed to the guidelines for its treatment.)\n##\n(\"entity\"<|>ALEXANDER EK<|>PERSON<|>Alexander EK is a researcher who contributed to the guidelines for the diagnosis and management of thyroid disease during pregnancy and postpartum.)\n##\n(\"entity\"<|>MEDULLARY THYROID CARCINOMA<|>EVENT<|>Medullary thyroid carcinoma is a type of thyroid cancer that arises from parafollicular C cells and is addressed in various clinical studies and guidelines.)\n##\n(\"entity\"<|>MICROADENOMA HIPOFISARIO<|>EVENT<|>Microadenoma hipofisario is a small pituitary tumor that can produce TSH and is relevant in differential diagnosis of thyroid hormone resistance.)\n##\n(\"entity\"<|>SÍNDROME DE RESISTENCIA A HORMONAS TIROIDEAS<|>EVENT<|>The syndrome of resistance to thyroid hormones is a condition where the body's tissues are resistant to thyroid hormones, complicating diagnosis and treatment.)\n##\n(\"relationship\"<|>WELLS SA<|>AMERICAN THYROID ASSOCIATION<|>Wells SA is involved in the development of guidelines by the American Thyroid Association for managing medullary thyroid carcinoma<|>8)\n##\n(\"relationship\"<|>ALEXANDER EK<|>AMERICAN THYROID ASSOCIATION<|>Alexander EK contributed to the guidelines provided by the American Thyroid Association for thyroid disease management<|>8)\n##\n(\"relationship\"<|>WELLS SA<|>EUROPEAN THYROID ASSOCIATION<|>Wells SA has also contributed to the European Thyroid Association's guidelines for thyroid conditions<|>7)\n##\n(\"relationship\"<|>ALEXANDER EK<|>EUROPEAN THYROID ASSOCIATION<|>Alexander EK's work is relevant to the European Thyroid Association's guidelines for thyroid disease<|>7)\n##\n(\"relationship\"<|>MEDULLARY THYROID CARCINOMA<|>WELLS SA<|>Wells SA has conducted research and contributed to the management guidelines for medullary thyroid carcinoma<|>9)\n##\n(\"relationship\"<|>MICROADENOMA HIPOFISARIO<|>SÍNDROME DE RESISTENCIA A HORMONAS TIROIDEAS<|>Microadenoma hipofisario is a condition that is differentiated from the syndrome of resistance to thyroid hormones<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158:239-46.\n- Meijer JA, Bakker LE, Valk GD, de Herder WW, de Wilt JH, Netea-Maier RT, et al. Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study. Eur J Endocrinol. 2013;168:779-86.\n- Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer. 2003;88:1537-42.\n- Wells SA, Asa SL, Dralle H, Elisei R, Evan DB, Gagel RFet al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid. 2015;25(6):567-610.\n- Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134-41\n\n## 3.8 Casos clínicos. Caso clínico 4\n\n### 56 Ante estos resultados ¿qué diagnósticos diferenciales se plantearía?\n\nA. Microadenoma hipofisario productor de TSH.\nB. Hipertiroxinemia en relación con gestación.\nC. Síndrome de resistencia a hormonas tiroideas.\nD. A y C.\n\nCOMENTARIO\n\nEsta pregunta plantea básicamente el caso de una mujer de 24 años, embarazada, a quien se detecta una T4 y una T3 elevadas, con TSH en el límite alto de la normalidad.\n\nEsta situación puede darse tanto en la resistencia a hormonas tiroideas como en los tumores productores de TSH, por lo que el diagnóstico diferencial debe establecerse fundamentalmente entre estos dos cuadros (opciones A y C ciertas: respuesta correcta D).\n\nEn cuanto a la opción B, es verdad que durante la gestación, especialmente durante el primer trimestre, puede darse un cuadro de hipertiroxinemia debido al efecto estimulante de la β-HCG sobre el receptor de la TSH. Sin embargo, en esta situación, la TSH endógena de la paciente se suprime (opción B falsa).\n\nReferencias:\n- Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27:315-89.\n- Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau J.-L. 2013 European Thyroid Association Guidelines for the Diagnosis and Treatment of Thyrotropin-Secreting Pituitary Tumors. Eur Thyroid J. 2013;2:76-82.\n- Ortiga-Carvalho TM, Sidhaye AR, Wondisford FE. Thyroid hormone receptors and resistance to thyroid hormone disorders. Nat Rev Endocrinol. 2014;10:582-91.\n\n### 57 Para el diagnóstico diferencial, ¿cuál de estas pruebas no aportaría datos significativos?\n\nA. Estudio genético del síndrome de resistencia a hormonas tiroideas.\nB. Tratamiento con antitiroideos\nC. Determinación de la subunidad α.\nD. Administración de T3 y posterior test de TRH.\n\nCOMENTARIO\n\nComo se ha expuesto en la pregunta anterior, el diagnóstico diferencial habría que establecerlo entre un microadenoma hipofisario productor de TSH y el síndrome de resistencia a hormonas tiroideas. Para llegar al diagnóstico de este último, habría que realizar estudio genético fundamentalmente del gen TRβ, localizado en el cromosoma 3, que alberga alrededor del 80% de las mutaciones descritas en este síndrome. Por lo tanto, el estudio genético puede aportar datos significativos.\n\nSi a un paciente con un hipertiroidismo por microadenoma hipofisario productor de TSH se le trata con antitiroideos, se frenará la producción de hormonas tiroideas, pero lo mismo pasará si hubiera una resistencia periférica a las mismas, por lo que la respuesta al tratamiento con antitiroideos no ayuda a distinguir entre ambas entidades. Por lo tanto, el tratamiento con antitiroideos no aporta datos significativos (opción B correcta).\n\nLa subunidad α puede estar elevada en los casos de tumores hipofisarios en un porcentaje que llega al 70%. Sin embargo, este porcentaje disminuye si los tumores causantes\n---\nson microadenomas. Así, en la serie de 43 TSHomas de Socin en la que 9 de los tumores eran microadenomas, el procentaje de posit\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}